Khiron Life Sciences Corp.

CVE: KHRN


Canadian symbol: KHRN.V
US symbol: KHRNF

Currency in CAD

Valuation Measures

Market Cap (intraday) 552.9M
Enterprise Value 335.89M
Trailing P/E N/A
Forward P/E 1-4.09
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)5.97
Price/Book (mrq)0.92
Enterprise Value/Revenue 34.05
Enterprise Value/EBITDA 6-1.03

Trading Information

Stock Price History

Beta (5Y Monthly) 1.99
52-Week Change 3-60.87%
S&P500 52-Week Change 314.38%
52 Week High 31.2300
52 Week Low 30.3000
50-Day Moving Average 30.4747
200-Day Moving Average 30.5650

Share Statistics

Avg Vol (3 month) 3255.59k
Avg Vol (10 day) 3156.08k
Shares Outstanding 5117.55M
Float 95.15M
% Held by Insiders 117.63%
% Held by Institutions 12.28%
Shares Short (Sep. 29, 2020) 4150.42k
Short Ratio (Sep. 29, 2020) 40.55
Short % of Float (Sep. 29, 2020) 4N/A
Short % of Shares Outstanding (Sep. 29, 2020) 40.13%
Shares Short (prior month Aug. 30, 2020) 477.07k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:8
Last Split Date 3May 23, 2018

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Jun. 29, 2020

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-400.50%

Management Effectiveness

Return on Assets (ttm)-26.42%
Return on Equity (ttm)-46.07%

Income Statement

Revenue (ttm)8.85M
Revenue Per Share (ttm)0.08
Quarterly Revenue Growth (yoy)-24.30%
Gross Profit (ttm)2.44M
EBITDA -34.94M
Net Income Avi to Common (ttm)-33.81M
Diluted EPS (ttm)-0.2950
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)20.05M
Total Cash Per Share (mrq)0.17
Total Debt (mrq)3.04M
Total Debt/Equity (mrq)5.28
Current Ratio (mrq)4.38
Book Value Per Share (mrq)0.49

Cash Flow Statement

Operating Cash Flow (ttm)-30.37M
Levered Free Cash Flow (ttm)-21.9M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
KHRN.V
Khiron Life Sciences
2 weeks ago
KHRN.V
Khiron Life Sciences
4 weeks ago
KHRN.V
Khiron Life Sciences
4 weeks ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
1 month ago
KHRN.V
Khiron Life Sciences
2 months ago
KHRN.V
Khiron Life Sciences
2 months ago
KHRN.V
Khiron Life Sciences
2 months ago
KHRN.V
Khiron Life Sciences
2 months ago
KHRN.V
Khiron Life Sciences
2 months ago
KHRN.V
Khiron Life Sciences
2 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
3 months ago
KHRN.V
Khiron Life Sciences
4 months ago
KHRN.V
Khiron Life Sciences
4 months ago
KHRN.V
Khiron Life Sciences
4 months ago
KHRN.V
Khiron Life Sciences
4 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
5 months ago
KHRN.V
Khiron Life Sciences
6 months ago
KHRN.V
Khiron Life Sciences
6 months ago
KHRN.V
Khiron Life Sciences
6 months ago
KHRN.V
Khiron Life Sciences
7 months ago
KHRN.V
Khiron Life Sciences
7 months ago
KHRN.V
Khiron Life Sciences
7 months ago
KHRN.V
Khiron Life Sciences
8 months ago
KHRN.V
Khiron Life Sciences
8 months ago
KHRN.V
Khiron Life Sciences
8 months ago
KHRN.V
Khiron Life Sciences
9 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
10 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
11 months ago
KHRN.V
Khiron Life Sciences
12 months ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago
KHRN.V
Khiron Life Sciences
1 year ago

Currency in CAD
Earnings EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts0011
Avg. Estimate00-0.23-0.11
Low Estimate00-0.23-0.11
High Estimate00-0.23-0.11
Year Ago EPS-0.11-0.09-0.36-0.23
Revenue EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts1111
Avg. Estimate1.9M2.8M10M43M
Low Estimate1.9M2.8M10M43M
High Estimate1.9M2.8M10M43M
Year Ago Sales2.21M2.77M9.58M10M
Sales Growth (year/est)-13.90%1.00%4.40%330.00%
Earnings History2019-06-292019-09-292019-12-302020-03-30
EPS Est.-0.09-0.08-0.09-0.09
EPS Actual-0.11-0.09-0.06-0.08
Difference-0.02-0.010.030.01
Surprise %-22.20%-12.50%33.30%11.10%
EPS TrendCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Current Estimate00-0.23-0.11
7 Days Ago-0.07-0.05-0.23-0.11
30 Days Ago-0.07-0.05-0.17-0.08
60 Days Ago-0.07-0.05-0.2-0.04
90 Days Ago-0.07-0.05-0.2-0.04
EPS RevisionsCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Up Last 7 DaysN/A1N/AN/A
Up Last 30 DaysN/A1N/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesKHRN.VIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.N/AN/AN/AN/A
Current Year36.10%N/AN/AN/A
Next Year52.20%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
17.63%% of Shares Held by All Insider
2.28%% of Shares Held by Institutions
2.77%% of Float Held by Institutions
8Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
AdvisorShares Investments, LLC543,329Jun. 29, 20200.46%293,397

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
AdvisorShares Trust-AdvisorShares Pure Cannabis ETF543,329Jun. 29, 20200.46%293,397
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Khiron Life Sciences Corp.


Khiron Appoints Joel Friedman to Succeed Wendy Kaufman as Chief Financial Officer

Khiron Appoints Joel Friedman to Succeed Wendy Kaufman as Chief Financial Officer

TORONTO, Oct. 19, 2020 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a medical cannabis leader with core operations in Latin America and Europe announced the appointment, effective October 16, of Joel Friedman as CFO following the resignation of Wendy Kaufman, the Company's CFO since July, 2019... Read More...
Khiron CEO to Present at Benzinga Virtual Cannabis Capital Conference

Khiron CEO to Present at Benzinga Virtual Cannabis Capital Conference

TORONTO, Oct. 14, 2020 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and director, will present live at the Benzinga Virtual Cannabis Capital Conferenc... Read More...
Company Reports Accelerated Increase in Medical Cannabis Prescriptions

Company Reports Accelerated Increase in Medical Cannabis Prescriptions

Khiron reaches more than 3,500 medical cannabis prescriptions filled Medical cannabis prescriptions increased by over 450% in Q3, compared to Q2 of 2020 Khiron's clinics exceeded 9,000 monthly patient consultations in September, marking a return to pre-pandemic monthly levels, supported by the launch of telehealth consultations Khiron... Read More...
Khiron To Present at Canaccord Genuity Virtual US Cannabis Symposium on September 30th

Khiron To Present at Canaccord Genuity Virtual US Cannabis Symposium on September 30th

TORONTO, Sept. 28, 2020 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that Alvaro Torres, Khiron CEO and Director, and Chris Naprawa, Khiron Chairman, will present live at Canaccord ... Read More...
Khiron Becomes First Company to Sell Medical Cannabis in Peru, and Surpasses 3,000 Prescriptions in Colombia

Khiron Becomes First Company to Sell Medical Cannabis in Peru, and Surpasses 3,000 Prescriptions in Colombia

First prescriptions for Khiron's medical cannabis in Peru are filled as the Company surpasses 3,000 medical cannabis prescription milestone in Colombia Khiron becomes the first Company to sell and fill medical cannabis prescriptions through private pharmacies in Peru The Company began sales in Peru with full spectrum High CBD supplied ... Read More...
Khiron Declared a National Strategic Project by the Government of Colombia

Khiron Declared a National Strategic Project by the Government of Colombia

Status Accelerates Ability to Bring New Products and Services to Market The National Interest Strategic Project certification ("PINES") was established by the Government of Colombia to prioritize the development of specific projects or companies that are deemed by the Government to be able to significantly increase the national economy ... Read More...
Khiron Announces Shareholder Approval of Amended and Restated Option Plan and Restricted Share Unit Plan, and Grants of RSUs

Khiron Announces Shareholder Approval of Amended and Restated Option Plan and Restricted Share Unit Plan, and Grants of RSUs

TORONTO, Sept. 11, 2020 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces the adoption of the Company's amended and restated stock option plan and the Company's amended and restated restricted share ... Read More...
Khiron Enters Exclusive Partnership with RAPPI, Latin America's Largest Home Multi-Vertical App Platform

Khiron Enters Exclusive Partnership with RAPPI, Latin America’s Largest Home Multi-Vertical App Platform

Rappi is the largest home multi-Vertical app in Latin America, which received a USD 1 Billion investment from Softbank Group Corp. and Softbank Vision Fund, reaching unicorn status in 2019. Rappi operates in Brazil, Colombia, Mexico, Argentina, Chile, Costa Rica, Uruguay, Ecuador and Peru, which together represent a population of over 60... Read More...
Khiron Announces Change of Auditor

Khiron Announces Change of Auditor

TORONTO, July 21, 2020 -- Khiron Life Sciences Corp. (‚ÄúKhiron‚Ä̬†or the ‚ÄúCompany‚ÄĚ) (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), announces that MNP LLP (the ‚ÄúFormer Auditor‚ÄĚ) have, at the request of the Company, resigned as auditors of the Company, effective July 10, 2020. Accordingly, the Board of Directors has appointed BDO Canada LL... Read More...
Khiron Signs Distribution Deal in Germany for Medical Cannabis Imports and Sales

Khiron Signs Distribution Deal in Germany for Medical Cannabis Imports and Sales

Khiron partners with Nimbus Health, a leading medical cannabis distributor in Germany, with broad reach into domestic pharmacies First import and sales of Khiron branded EU GMP medical cannabis products are expected in Q3/20 Medical education and marketing activities to begin imminently Germany is the largest medical cannabis market i... Read More...
Khiron Goes Green, Completing 1 Megawatt Solar Energy Park in Colombia

Khiron Goes Green, Completing 1 Megawatt Solar Energy Park in Colombia

Developed with ReFeel, a leading Italian renewable Company with more than 80 MW installed in Europe and Latin America, Khiron's solar park is expected to generate up to 700 kWh through a photovoltaic (PV) system that comprises 2,618 installed solar panels. With the construction of the PV system, Khiron can self-generate up to 40% of the ... Read More...
Khiron Appoints Chris Naprawa to Director, and Chairman of the Board

Khiron Appoints Chris Naprawa to Director, and Chairman of the Board

TORONTO, June 12, 2020 - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces today the appointment of Chris Naprawa as Director and  Chairman of the Board. In transitioning from his curr... Read More...
Khiron Life Sciences Reports First Quarter Fiscal 2020 Financial Results

Khiron Life Sciences Reports First Quarter Fiscal 2020 Financial Results

Closed quarter with net working capital of $28.4 million Achieved revenues of $1.9 Million for Q1 2020, improving gross margin by 17% compared to Q1 2019 Achieved first sales in Colombia of low-THC medical cannabis, and subsequent to the quarter, began its first high-THC medical cannabis sales in Colombia on May 19th 2020 Increased re... Read More...
Khiron Receives First Medical Cannabis Prescriptions for UK Patients Participating in Project Twenty21

Khiron Receives First Medical Cannabis Prescriptions for UK Patients Participating in Project Twenty21

Khiron is the exclusive Latin American supplier to Project Twenty21, a leading UK registry study enrolling up to 20,000 patients by the end of 2021, to create the largest body of evidence in Europe for the effectiveness and tolerability of medical cannabis First import of EU GMP medical cannabis products is complete Khiron branded produc... Read More...
Khiron Life Sciences Reports 2019 Fiscal Year End Results and Provides Corporate Update

Khiron Life Sciences Reports 2019 Fiscal Year End Results and Provides Corporate Update

Net working capital of $36.4 Million CAD at December 31, 2019 On March 20, 2020 Khiron became the first and only company in Colombia to receive full authorization to manufacture high- and low-THC medical cannabis, and to fill prescriptions for low-THC medical cannabis Khiron became the only Company authorized to export THC products Fi... Read More...
Khiron Signs Exclusive Agreement with Medlive, a Distributor Serving 3,000 Clinics and Hospitals in Brazil

Khiron Signs Exclusive Agreement with Medlive, a Distributor Serving 3,000 Clinics and Hospitals in Brazil

Exclusive agreement with Medlive, a pharmaceutical and health products distributor with network of over 3,000 clinics and hospitals in southern Brazil Company's medical cannabis products will be marketed through Medlive network of doctor offices, clinics, hospitals and governmental institutions Medical education, marketing activities a... Read More...
Khiron Provides Update on Filing of its 2019 Year End Results

Khiron Provides Update on Filing of its 2019 Year End Results

Company filing date moved from April 29 to estimate of May 1 to allow auditors to complete audit delayed as a result of COVID-19 situation  Filing extension provided by Ontario Securities Commission on March 23, 2020 in response to COVID-19 pandemic TORONTO, April 28, 2020 - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV... Read More...
Khiron to Report 2019 Fiscal Year End Results and Provides Corporate Update

Khiron to Report 2019 Fiscal Year End Results and Provides Corporate Update

Khiron to report Q4 and Year End Results on April 28, and webcast Q&A will be held the following day Khiron finished the 2019 calendar year with approximately $36 Million CAD in cash and working capital Khiron and its clinics operational during COVID-19 pandemic under an exemption decreed by the Government of Colombia, without any ... Read More...
Khiron to Educate Physicians on Medical Cannabis Online with Leading Latin American University

Khiron to Educate Physicians on Medical Cannabis Online with Leading Latin American University

Agreement with Tecnologico de Monterrey, a leading Latin American university (Third Ranked in Latin America) in Mexico brings Khiron¬īs online education program to reach 1,500 physicians, healthcare practitioners and beyond Doctor education continues to be core to Khiron mission Partnership allows Khiron to include its medical education ... Read More...
Khiron Meets Essential Patient Needs with Launch of Teleconsultation Services in Colombia

Khiron Meets Essential Patient Needs with Launch of Teleconsultation Services in Colombia

Starting April 1st, Company's virtual consultation service gives patients access to clinic services and doctors trained to prescribe medical cannabis Teleconsultation service anticipated to quickly expand to meet potential growing demand for telehealth services, including Company's 120,000 patients from its ILANS and Zerenia clinics Kh... Read More...
Khiron Readies for First Medical Sales in Colombia and Provides Corporate Update

Khiron Readies for First Medical Sales in Colombia and Provides Corporate Update

Effective immediately, Khiron is fully authorized to manufacture high- and low-THC medical cannabis, and to fill prescriptions for low-THC medical cannabis Khiron anticipates filling its first revenue generating patient prescriptions within days With successful lab certification, Khiron becomes the first company authorized to sell medi... Read More...
Khiron is First Company Authorized to Extract High THC Medical Cannabis in Colombia

Khiron is First Company Authorized to Extract High THC Medical Cannabis in Colombia

Further to cultivation quotas announced on February 26, 2020, this authorization by the Colombian Technical Quotas Authority ("TQG") allows the Company to now produce oils for sale both domestically and abroad. Of the 9.3 tonnes approved, 50% are for Colombian domestic use and 50% are allowed for export purposes. Export quotas allow fo... Read More...
Khiron Granted Approval to Cultivate 9.3 Tons of THC Cannabis, Representing 17% of the Total Allocated Quota for Colombia in 2020

Khiron Granted Approval to Cultivate 9.3 Tons of THC Cannabis, Representing 17% of the Total Allocated Quota for Colombia in 2020

Colombia was granted a total production quota of 56.2 tons of medical cannabis for 2020 by the International Narcotics Control Board ("INCB"), the entity responsible for the implementation of the United Nations drug conventions. This represents 21.9% of the world¬īs legal global supply of high THC medical cannabis. The Company will beg... Read More...
Khiron to Participate in 3rd Annual Gravitas Growth Conference in Vancouver, BC

Khiron to Participate in 3rd Annual Gravitas Growth Conference in Vancouver, BC

TORONTO, Feb. 14, 2020 - Khiron Life Sciences Corp. ("Khiron") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, is pleased to announce it will be participating in the 3rd Annual Gravitas Growth Conference taking place February 20th, 2020 at the Fairmont Pacif... Read More...
Khiron Increases Clinical Capacity in Colombia by 75% with Opening of Zerenia Integrated Medical Clinic

Khiron Increases Clinical Capacity in Colombia by 75% with Opening of Zerenia Integrated Medical Clinic

Zerenia offers a person-centered integrated care model, with the concept of integrative medicine combining traditional and complementary medicine, and with evidence-based treatments and high professional practices. Services are delivered across multiple clinical units include: Pain management, mental health, surgical, neurology and ... Read More...
Khiron CEO Alvaro Torres to Present at AltaCorp/ATB 8th Annual Institutional Investor Conference

Khiron CEO Alvaro Torres to Present at AltaCorp/ATB 8th Annual Institutional Investor Conference

TORONTO, Jan. 6, 2020 - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that CEO and Director Alvaro Torres will speak on the International Expansion panel at the AltaCorp/ATB 8th Annual ... Read More...
Khiron Welcomes Colombia's Receipt of 2020 Production Quota of 56.5 Tons of High-THC Cannabis

Khiron Welcomes Colombia’s Receipt of 2020 Production Quota of 56.5 Tons of High-THC Cannabis

Khiron the only LP with a 2019 quota that authorizes the Company to manufacture high-THC whole plant extract and produce customized medical cannabis prescriptions for domestic use 56.5 tons, or 21.84% of global supply of high THC medical cannabis for commercial and scientific purposes assigned to Colombia for 2020 by International Nar... Read More...
Khiron Welcomes Regulatory Guidelines in Peru, Announces Good Storage Practices Certification

Khiron Welcomes Regulatory Guidelines in Peru, Announces Good Storage Practices Certification

Peruvian authorities to allow businesses to begin applications for medical cannabis licenses, and further outline a clear licensing process Khiron has secured Good Storage Practices (GSP) certification, a crucial prerequisite for import and commercialization license applications in Peru Company has submitted its security protocols f... Read More...
Khiron Announces Chairman Transition and Appointment of Audit Committee Chair

Khiron Announces Chairman Transition and Appointment of Audit Committee Chair

TORONTO, Nov. 29, 2019 - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, today announced that Sidney Himmel has resigned as Director and Chair of the Board to pursue other interests, effective immediatel... Read More...
Khiron Reports Q3 Fiscal 2019 Financial Results, With $47.9 Million Cash Balance and $2.8 Million in Quarterly Revenue

Khiron Reports Q3 Fiscal 2019 Financial Results, With $47.9 Million Cash Balance and $2.8 Million in Quarterly Revenue

Ended the quarter with $47.9 million in cash and short-term investments Robust balance sheet puts Company in a position of strength ILANS clinics showed progressively stronger margins and an over 20% increase in revenues in Q3 Multi-country strategy advances with TSX-V approval for distribution and sale of Kuida CBD products in th... Read More...
Khiron Receives First Colombian Authorization to Commercialize High-THC Cannabis for Domestic and Export Sales

Khiron Receives First Colombian Authorization to Commercialize High-THC Cannabis for Domestic and Export Sales

Authorization for domestic and export purposes comes as a result of commercial quotas allocated to Khiron by the Colombian Technical Quotas Group ("TQG") for 2019 Permits Company to cultivate and commercialize psychoactive cannabis Includes authorization to export of whole plant extract to Uruguay and Brazil Positions Khiron to as... Read More...
View from the C-Suite: Franziska Katterbach, Chief Legal Officer, Khiron Life Sciences Corp. Europe, tells her company's story. Filmed on October 16, 2019

View from the C-Suite: Franziska Katterbach, Chief Legal Officer, Khiron Life Sciences Corp. Europe, tells her company’s story. Filmed on October 16, 2019

TORONTO , Nov. 20, 2019 -https://www.youtube.com/watch?v=eWAWlCVmecMThe View from the C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange.  Videos provide insight into how company executives think in the current business environment.  To see the latest Vi... Read More...
Coming Soon.
SymbolExchangePriceChangeAs of
KHRN.V
TSX Venture Exchange (former Canadian Ventures Exchange)
TSX Venture Exchange (former Canadian Ventures Exchange)0.45CAD0.00%
4KH.F
Frankfurt Stock Exchange
Frankfurt Stock Exchange0.29EUR-2.98%
KHRN.CCP
Canadian Composite Quote/Trade
Canadian Composite Quote/Trade0.45CAD-4.26%
4KH.BE
Berlin Stock Exchange
Berlin Stock Exchange0.29EUR+0.35%
4KH.H
Hamburg Stock Exchange
Hamburg Stock Exchange0.28EUR-4.80%
KHRNF.PK
US 'Other OTC' and Grey Market
US 'Other OTC' and Grey Market0.35USD+1.03%
4KH.D
Dusseldorf Stock Exchange
Dusseldorf Stock Exchange0.28EUR+0.07%
4KH.MU
Munich Stock Exchange
Munich Stock Exchange0.30EUR-2.62%
4KH.SG
Stuttgart Stock Exchange
Stuttgart Stock Exchange0.28EUR+1.06%
KHRN.GO
Canadian Securities Exchange/PURE - CSE Listed & Other Canadian Listed Securities
Canadian Securities Exchange/PURE - CSE Listed & Other Canadian Listed Securities0.45CAD0.00%

Delayed data (1h)
NameAgePositionAppointed
Alvaro Torres
Interim Chairman of the Board, Chief Executive Officer
--Interim Chairman of the Board, Chief Executive Officer2019
Chris Naprawa
President
--President2018
Darren Collins
Chief Financial Officer, Corporate Secretary
35Chief Financial Officer, Corporate Secretary--
Wendy Kaufman
Chief Financial Officer
--Chief Financial Officer2019
Vicente Fox Quesada
Director
--Director2018
Deborah E. Rosati
Director
56Director2019
Sruli Weinreb
Director
--Director2017


Share this page